The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

filing / Aug 10, 2026 / receipt

The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services.

filing / Aug 10, 2026 / receipt

The increase was also driven by (i) $3.4 million of higher employee-related costs as a result of increased headcount to support the expansion of our research and development activities, which includes $1.3 million of higher stock-based compensation expenses as a result of additional new equity grants during the period, and (ii) $0.3 million in other research and development expense, partially offset by $0.6 million o

filing / Aug 10, 2026 / receipt

The increase was also driven by (i) $8.1 million of higher employee-related costs as a result of increased headcount to support the expansion of our research and development activities, which includes $3.1 million of higher stock-based compensation expenses as a result of additional new equity grants during the period, (ii) $0.9 million in other research and development expense, and (iv) $0.4 million of higher facili

filing / Aug 10, 2026 / receipt

The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs.

filing / May 11, 2026 / receipt

The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services.

filing / May 11, 2026 / receipt

General and administrative expenses were $10.3 million and $6.9 million for the three months ended March 31, 2026 and 2025, respectively, primarily due to $3.4 million of higher employee-related costs as a result of increased headcount to support our growing operations.

filing / May 11, 2026 / receipt

Senior Director, Regulatory Affairs | {"ats": "greenhouse", "city": "South San Francisco", "state": "CA", "job_id": "5424099008", "remote": false, "category": "other", "function": "legal", "location":

company_statement / Sep 14, 2026 / receipt

Associate Director, Process Chemistry | {"ats": "greenhouse", "city": "South San Francisco", "state": "CA", "job_id": "5387012008", "remote": false, "category": "other", "function": "retail", "locatio

company_statement / Aug 11, 2026 / receipt

Research Associate, Translational Biology (CONTRACT) | {"ats": "greenhouse", "city": "South San Francisco", "state": "CA", "job_id": "5363412008", "remote": false, "category": "other", "function": "re

company_statement / Jul 17, 2026 / receipt

Director, Program and Portfolio Management | {"ats": "greenhouse", "city": "South San Francisco", "state": "CA", "job_id": "5324552008", "remote": false, "category": "other", "function": "other", "loc

company_statement / Jul 10, 2026 / receipt